Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: A.I. Hernandez Cordero has nothing to disclose.
Conflict of interest: C.X. Yang has nothing to disclose.
Conflict of interest: S. Milne has nothing to disclose.
Conflict of interest: X. Li has nothing to disclose.
Conflict of interest: Z. Hollander reports funding from Genome Canada, Genome British Columbia, Genome Quebec, the Canadian Institutes of Health Research, PROOF Centre of Excellence, St. Paul's Hospital Foundation and Providence Health Care for the Rapid Transition Program (RTP) cohort included in the manuscript.
Conflict of interest: V. Chen reports funding from Genome Canada, Genome British Columbia, Genome Quebec, the Canadian Institutes of Health Research, PROOF Centre of Excellence, St. Paul's Hospital Foundation and Providence Health Care for the Rapid Transition Program (RTP) cohort included in the manuscript.
Conflict of interest: R. Ng reports funding from Genome Canada, Genome British Columbia, Genome Quebec, the Canadian Institutes of Health Research, PROOF Centre of Excellence, St. Paul's Hospital Foundation and Providence Health Care for the Rapid Transition Program (RTP) cohort included in the manuscript.
Conflict of interest: S.J. Tebbutt has nothing to disclose.
Conflict of interest: J.M. Leung reports research research grant funding to their institution from Canadian Institutes of Health Research, Michael Smith Foundation for Health Research, BC Lung Association and Genome BC, outside the scope of the current manuscript.
Conflict of interest: D.D. Sin declares grants from AstraZeneca for an investigator-initiated randomised controlled trial in COPD; consulting fees from Novaira for sitting on an advisory board for COPD; and honoraria for speaking engagements from AstraZeneca, Boehringer Ingelheim and Grifols, all in the 36 months prior to manuscript submission.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org